|
|
Center Park II., Suite 320, 4061 Powdermill Road
Calverton, MD 20705 USA
phone:(301) 617-9080
fax:(301) 617-9075
|
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.metamorphixinc.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Treatment of human muscular degenerative diseases, as well as Type II diabetes and obesity. |
|
| Management |
| Dr. Edwin Quattlebaum , Ph.D, Co-Chairman, President and CEO; Thomas P. Russo, Executive Vice President and CFO; Dr. Dennis Fantin , MBA, Ph.D, Executive Vice President, Chief of Operations; Dr. Linda Yaswen-Corkery , Ph.D, Chief Compliance Officer & Vice President - Strategic Planning; victoria Geis, Vice President, Human Resources; Sue DeNise , Ph.D, Vice President of Genomic Research and Development; Dr. Li-Fang Liang , Ph.D, Director Molecular Biology Discovery; David Rosenfeld, Director, Software Development and Bioinformatics; Michael McGuire, C.P.A., Group controller and Director |
| |
|
|
| |
|
| Keywords |
| Type II Diabetes, blood sugar, diabetic, metabolic, insulin, obesity, muscular degenerative |
|
|
|
| Description |
|
MetaMorphix's internal focus is on near-term agricultural opportunities and establishing pharmaceutical partnerships for human therapeutic opportunities. |
|
| Products / Services |
MetaMorphix expects to receive substantial milestone and royalty payments from the pharmaceutical development of Myostatin for treatment of human muscular degenerative diseases, as well as Type II diabetes and obesity.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members